Y-mAbs Therapeutics Newsroom

JonesTrading Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $23

Moomoo NewsDec 13 15:31 ET · Ratings

Promising Preclinical Data on CD38-SADA Justifies Buy Rating for Y-Mabs Therapeutics

TipRanksDec 11 06:26 ET · Ratings

CCORF Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $26

Moomoo NewsDec 9 08:31 ET · Ratings

Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting

Y-mAbs TherapeuticsDec 7 00:00 ET

Brookline Capital Initiates Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Announces Target Price $17

Moomoo NewsDec 5 12:31 ET · Ratings

Decoding 5 Analyst Evaluations For Y-mAbs Therapeutics

BenzingaDec 5 08:01 ET

Y-mAbs Therapeutics Initiated With a Buy at Brookline on Danyelza Potential

TipRanksDec 5 06:25 ET · Ratings

Brookline Capital Initiates Coverage On Y-mAbs Therapeutics With Buy Rating, Announces Price Target of $17

BenzingaDec 5 05:16 ET · Ratings

Benign Growth For Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Underpins Stock's 28% Plummet

Simply Wall StDec 4 06:06 ET

Y-mAbs to Participate at Citi's 2024 Global Healthcare Conference

Y-mAbs TherapeuticsNov 27 00:00 ET

Oppenheimer Initiates Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Announces Target Price $23

Moomoo NewsNov 19 03:36 ET · Ratings

Beyond The Numbers: 4 Analysts Discuss Y-mAbs Therapeutics Stock

BenzingaNov 18 09:00 ET

Oppenheimer Initiates Coverage On Y-mAbs Therapeutics With Outperform Rating, Announces Price Target of $23

BenzingaNov 18 08:48 ET · Ratings

Y-mAbs Therapeutics Analyst Ratings

BenzingaNov 15 14:12 ET · Ratings

H.C. Wainwright Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $22

Moomoo NewsNov 15 08:31 ET · Ratings

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Institutional Investors Lost 13% Last Week but Have Benefitted From Longer-term Gains

Simply Wall StNov 13 08:00 ET

JonesTrading Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $23

Moomoo NewsNov 11 15:31 ET · Ratings

Truist Financial Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Announces Target Price $21

Moomoo NewsNov 11 07:31 ET · Ratings

Truist Financial Remains a Buy on Y-Mabs Therapeutics (YMAB)

TipRanksNov 11 07:29 ET · Ratings

Y-Mabs Therapeutics: Promising Pipeline Developments and Strong Revenue Projections Justify Buy Rating

TipRanksNov 11 06:56 ET · Ratings